I agree that this site is using cookies. You can find further informations here.
X
Freshwater, Tomoko
38  results:
Search for persons X
?
1

A phase 1 trial of the MEK inhibitor selumetinib in combina..:

Chénard-Poirier, Maxime ; Hansen, Aaron R. ; Gutierrez, Martin E....
Investigational New Drugs.  42 (2024)  3 - p. 241-251 , 2024
Link: https://doi.org/10.1007/..
 
?
2

Correction to: CXCR2 antagonist navarixin in combination wi..:

Armstrong, Andrew J. ; Geva, Ravit ; Chung, Hyun Cheol...
Investigational New Drugs.  42 (2024)  3 - p. 340-341 , 2024
Link: https://doi.org/10.1007/..
 
?
3

Disentangling Anti‐Tumor Response of Immunotherapy Combinat..:

Sancho‐Araiz, Aymara ; Parra‐Guillen, Zinnia P. ; Troconiz, Iñaki F..
Clinical Pharmacology & Therapeutics.  , 2024
Link: https://doi.org/10.1002/..
 
?
4

CXCR2 antagonist navarixin in combination with pembrolizuma..:

Armstrong, Andrew J. ; Geva, Ravit ; Chung, Hyun Cheol...
Investigational New Drugs.  42 (2024)  1 - p. 145-159 , 2024
Link: https://doi.org/10.1007/..
 
?
5

A Population Pharmacokinetic Assessment of the Effect of Fo..:

Zuo, Peiying ; Arefayene, Million ; Pan, Wei‐Jian..
Clinical Pharmacology in Drug Development.  13 (2024)  7 - p. 770-781 , 2024
Link: https://doi.org/10.1002/..
 
?
6

Assessment of Clinical Response to V937 Oncolytic Virus Aft..:

Parra‐Guillen, Zinnia P. ; Sancho‐Araiz, Aymara ; Mayawala, Kapil...
Clinical Pharmacology & Therapeutics.  114 (2023)  3 - p. 623-632 , 2023
Link: https://doi.org/10.1002/..
 
?
7

A physiologically based pharmacokinetic model for V937 onco..:

Peribañez-Dominguez, Sara ; Parra-Guillen, Zinnia P. ; Freshwater, Tomoko.
Frontiers in Pharmacology.  14 (2023)  - p. , 2023
Link: https://doi.org/10.3389/..
 
?
8

Results of an open-label phase 1b study of the ERK inhibito..:

Stathis, Anastasios ; Tolcher, Anthony W. ; Wang, Judy S....
Investigational New Drugs.  41 (2023)  3 - p. 380-390 , 2023
Link: https://doi.org/10.1007/..
 
?
9

High-Resolution Ex Vivo Tissue Clearing, Lightsheet Imaging..:

Kumar, Niyanta ; Hrobař, Petr ; Vagenknecht, Martin...
Microscopy and Microanalysis.  28 (2022)  S1 - p. 1436-1437 , 2022
Link: https://doi.org/10.1017/..
 
?
10

Population pharmacokinetics and exposure–response of selume..:

Schalkwijk, Stein ; Zhou, Li ; Cohen‐Rabbie, Sarit...
Cancer Chemotherapy and Pharmacology.  88 (2021)  2 - p. 189-202 , 2021
Link: https://doi.org/10.1007/..
 
?
11

Pivotal Dose of Pembrolizumab: A Dose‐Finding Strategy for ..:

Li, Tommy R. ; Chatterjee, Manash ; Lala, Mallika...
Clinical Pharmacology & Therapeutics.  110 (2021)  1 - p. 200-209 , 2021
Link: https://doi.org/10.1002/..
 
?
12

Mechanistic Modeling of a Novel Oncolytic Virus, V937, to D..:

Parra-Guillen, Zinnia P. ; Freshwater, Tomoko ; Cao, Youfang...
Frontiers in Pharmacology.  12 (2021)  - p. , 2021
Link: https://doi.org/10.3389/..
 
?
13

Physiologically Based Pharmacokinetic Modeling for Selumeti..:

Cohen‐Rabbie, Sarit ; Zhou, Li ; Vishwanathan, Karthick...
The Journal of Clinical Pharmacology.  61 (2021)  11 - p. 1493-1504 , 2021
Link: https://doi.org/10.1002/..
 
?
14

Immunogenicity of pembrolizumab in patients with advanced t..:

van Vugt, Marianne J. H. ; Stone, Julie A. ; De Greef, "Rik" H. J. M. M....
Journal for ImmunoTherapy of Cancer.  7 (2019)  1 - p. , 2019
Link: https://doi.org/10.1186/..
 
?
15

Aristolochic Acid I Metabolism in the Isolated Perfused Rat..:

Priestap, Horacio A. ; Torres, M. Cecilia ; Rieger, Robert A....
Chemical Research in Toxicology.  25 (2011)  1 - p. 130-139 , 2011
Link: https://doi.org/10.1021/..
 
1-15